Clinical Trial: A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients with Advanced Solid Tumors with KRAS Mutations

U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT06835569) titled 'A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients with Advanced Solid Tumors with KRAS Mutations' on Feb. 14.

Brief Summary: The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Cancer PDAC - Pancreatic Ductal Adenocarcinoma NSCLC (non-small Cell Lung Cancer) CRC (colorectal Cancer) Advanced Solid Tumors

Intervention: DRUG: ALTA3263

Oral ALTA3263 tablets will be administered at a protocol-defined dose

Recruitment Status: RECRUITING

Sponsor: Alterome Therapeuti...